Zacks Research Analysts Decrease Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Zacks Research cut their FY2024 earnings per share estimates for Theravance Biopharma in a report issued on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of ($0.89) per share for the year, down from their prior forecast of ($0.87). The consensus estimate for Theravance Biopharma's current full-year earnings is ($0.83) per share. Zacks Research also issued estimates for Theravance Biopharma's Q4 2024 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at $0.84 EPS.

Several other equities research analysts have also commented on TBPH. Evercore ISI lowered Theravance Biopharma from an "outperform" rating to an "inline" rating in a research note on Monday, January 8th. BTIG Research initiated coverage on Theravance Biopharma in a research report on Friday, April 12th. They issued a "buy" rating and a $21.00 target price for the company.

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded down $0.17 during trading on Wednesday, hitting $9.52. The company's stock had a trading volume of 307,877 shares, compared to its average volume of 384,694. The stock has a market capitalization of $462.29 million, a price-to-earnings ratio of -9.81 and a beta of 0.36. The stock's fifty day moving average is $8.98 and its 200 day moving average is $9.66. Theravance Biopharma has a 1-year low of $8.21 and a 1-year high of $11.98.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. The company had revenue of $17.57 million during the quarter, compared to analysts' expectations of $17.49 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG boosted its holdings in Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 1,101 shares during the last quarter. Point72 Middle East FZE purchased a new position in Theravance Biopharma in the fourth quarter valued at about $41,000. Tower Research Capital LLC TRC boosted its holdings in Theravance Biopharma by 116.1% in the second quarter. Tower Research Capital LLC TRC now owns 4,015 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 2,157 shares during the last quarter. Quantbot Technologies LP bought a new position in Theravance Biopharma during the 2nd quarter worth approximately $62,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Theravance Biopharma by 324.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 4,402 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.